The Family Planning Association is looking for 300 women for a four year study with a vaccine intended to prevent infection with human papillomavirus - the virus that causes most cervical cancer.
Developed by Merck Sharp and Dohme, the vaccine has already been received by 2,700 women worldwide in phase one and phase two clinical studies.
The New Zealand women being recruited will be among 5000 in 13 countries taking part in this major phase three study.
The four main types of human papillomavirus are responsible for cervical cancer and genital warts. It is estimated that more than half of all sexually active adults will be infected with this virus at some stage in their life.
